Malignant melanoma: PET/CT as a staging procedure

Frontiers of Radiation Therapy and Oncology

Volumn 39, Issue , 2006, Pages 159-170

  Müller, Stefan P ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MELANOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SKIN TUMOR; WHOLE BODY IMAGING;

FLUORODEOXYGLUCOSE F18; HUMANS; MELANOMA; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 33644633278     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (48)

1. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
2. Essner R, Lee JH, Wanek LA, Itakura H, Morton DL: Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 2004;139:961-966; discussion 966-967.
3. Phelps ME, Cherry SR: The changing design of positron imaging systems. Clin Positron Imaging 1998;1:31-45.
4. Zanzonico P: Positron emission tomography: A review of basic principles, scanner design and performance, and current systems. Semin Nucl Med 2004;34:87-111.
5. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
6. 18F-2-fluoro-2-deoxy-D- glucose. Acta Neurol Scand Suppl 1977;64:190-191.
7. 18F]2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol 1979;6:371-388.
8. Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, Lewellen TK, Lewellen B, Freeman SD, Berger MS, Ojemann GA: Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant. J Nucl Med 1998;39:440-448.
9. Gambhir SS, et al: A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(5 suppl):1S.
10. Reske SN, Kotzerke J: FDG-PET for clinical use: Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med 2001;28:1707-1723.
11. 18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-1782.
12. Kuwert T, et al: Klinische Wertigkeit der Positronen-Emissions- Tomographie in der Neuromedizin. Positionspapier zu den Ergebnissen einer interdisziplinaren Konsensuskonferenz. Nervenarzt 1998;69:1045-1060.
13. Schwaiger M, Pirich C: Positronen-Emissions-Tomographie. Z Kardiol 2000;1:59-66.
14. Keyes JW Jr: SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-1839.
15. Beyer T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.
16. Beyer T, et al: Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004;45 (suppl 1):25S-35S.
17. Antoch G, et al: Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 2004;22:4357-4368.
18. Bar-Shalom R, et al: Clinical performance of PET/CT in evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-1209.
19. Lardinois D, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507.
20. Ling CC, et al: Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-560.
21. Leiter U, et al: Prognostic factors of thin cutaneous melanoma: An analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol 2004;22:3660-3667.
22. Wagner JD, et al: Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-1515.
23. Wagner JD, et al: FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77:231-242.
24. Wagner JD, et al: Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol 1999;6:398-404.
25. Acland KM, et al: Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674-2678.
26. 18FDG PET imaging versus sentinel node detection. Oncologist 2002;7:271-278.
27. Havenga K, et al: Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29:662-664.
28. Longo MI, et al: Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg 2003;29:245-248.
29. Fink AM, et al: Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 2004;14:141-145.
30. 18F]-2- deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-1776.
31. 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients. Cancer 1998;82:1664-1671.
32. Wagner JD, et al: Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181-189.
33. Tyler DS, et al: Positron emission tomography scanning in malignant melanoma. Cancer 2000;89:1019-1025.
34. Finkelstein SE, et al: A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 2004;11:731-738.
35. Grippa F, et al: Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-1494.
36. Swetter S, et al: Positron emission tomography (PET) is superior to computerized tomography (CT) for metastatic staging in melanoma patients. Clin Positron Imaging 2000;3:154.
37. 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J 2001;17:802-820.
38. Gritters LS, et al: Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-1427.
39. Boni R, et al: Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556-562.
40. Blessing C, et al: Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995;131:1394-1398.
41. Damian DL, et al: Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-329.
42. Steinert HC, et al: Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705-709.
43. Hsueh EC, et al: Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191-197.
44. Gulec SA, et al: The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: Impact on surgical decision making. Clin Nucl Med 2003;28:961-965.
45. Holder WD Jr, et al: Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-769; discussion 769-771.
46. Eigtved A, et al: Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-75.
47. Stas M, et al: 18-FDG PET scan in the staging of recurrent melanoma: Additional value and therapeutic impact. Melanoma Res 2002;12:479-490.
48. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45:1323-1327.